Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

2.125 +0.325 (+18.06%)
Streaming Delayed Price Updated: 2:16 PM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Expedia Group, Gartner, Cloudflare, Cardinal Health And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Earnings Outlook For Allogene Therapeutics ↗
 
Via Benzinga
News headline image
Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in November Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Ratings for Allogene Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Outlook For Allogene Therapeutics ↗
 
Via Benzinga
News headline image
Analyst Ratings for Allogene Therapeutics ↗
 
Via Benzinga
News headline image
Why Allogene Stock Is Trading Down Today ↗
Allogene Therapeutics, Inc. (NASDAQ: ALLO) shares are trading lower after the company announced its CFO Eric Schmidt will step down from his position. 
Via Benzinga
News headline image
Allogene Therapeutics to Report Third Quarter 2023 Financial Results on November 2, 2023
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET 
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
A Bull Market Is Coming: 1 Beaten-Down Growth Stock You Could Regret Not Buying on the Dip ↗
Wall Street price targets suggest this stock can rocket more than 400% higher. 
Via The Motley Fool
News headline image
Vail Resorts, Carnival, Opera And Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded higher, with the Nasdaq Composite gaining around 1% on Friday. Here are some big stocks recording losses in today’s session. Corcept Therapeutics Incorporated (NASDAQ: CORT) shares... 
Via Benzinga
Topics Stocks
News headline image
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Participation in September Investor Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Next Meme Stock: 6 Tickers Leading a Meme Stock Revival
Meme stocks soared during the early days of the pandemic. Will these stocks form a major meme stock rally or a short-lived farewell tour? Learn more. 
Via MarketBeat
News headline image
Allogene Therapeutics Appoints Earl Douglas as General Counsel
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Stocks With Sky-High Short Interest Levels
BYND, BTAI, and ALLO stand out as high short-interest stocks to watch due to their potential for price fluctuations and short-squeeze opportunities. 
Via MarketBeat
News headline image
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Short Squeeze Alert: The 5 Most Shorted Stocks Right Now ↗
Wondering what are the most shorted stocks this year? Here are the top five companies investors are betting against. 
Via InvestorPlace
News headline image
Allogene Therapeutics' Allogeneic CAR-T Therapy Proves Potential for LBCL Treatment, Analysts See Potential for First-in-Class Status ↗
Thursday, Allogene Therapeutics Inc (NASDAQ: ALLO) presented the updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T naïve patients with relapsed/refractory (r/r) large... 
Via Benzinga
News headline image
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial... 
Via Benzinga
News headline image
Allogene Therapeutics Announces Departure of Chief Financial Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.